Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) Bundle
Founded in 1999 and publicly listed on the Shanghai Stock Exchange in 2000, Henan Lingrui Pharmaceutical Co., Ltd. has grown into a multi-subsidiary firm that blends traditional Chinese medicine with modern manufacturing-anchored by its largest production base in Xin County focused on adhesive plasters-and today exports to more than 30 countries while reporting revenue of 2.33 billion yuan in 2020; driving this expansion is a heavy investment in innovation, with R&D spending of about 150 million yuan (≈12.5% of revenue) in 2022, a mission to improve global health through safe, GMP-compliant products, a vision to become a first-class global biopharmaceutical enterprise by 2025, and core values that translate into tangible social impact-over 20 million RMB donated to disaster relief, infrastructure and welfare projects and more than 10,000 people lifted out of poverty-underscoring Lingrui's strategic focus on quality, sustainability, and community-driven growth.
Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) - Intro
Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) is a China-based pharmaceutical manufacturer established in 1999 and listed on the Shanghai Stock Exchange in 2000. The company combines traditional Chinese medicine (TCM) heritage with modern pharmaceutical manufacturing, producing tablets, injections, ointments, adhesive plasters and Chinese patent medicines for domestic and international markets. Its largest production base, centered on adhesive plaster manufacturing, is located in Xin County, Henan Province. Lingrui exports products to more than 30 countries and recorded revenue of 2.33 billion yuan in 2020.- Core product categories: tablets, injections, ointments, adhesive plasters, Chinese patent medicines
- Manufacturing footprint: multiple subsidiaries and research centers; principal production base in Xin County, Henan
- International reach: exports to 30+ countries
- 2020 financial marker: revenue of 2.33 billion yuan
Mission
The company's mission centers on developing safe, effective and accessible healthcare products by integrating TCM principles with contemporary pharmaceutical standards. Key mission drivers include patient-centered safety, evidence-based efficacy, scalable manufacturing, and expanding access to natural and alternative medicines globally.- Ensure product safety and regulatory compliance across domestic and export markets
- Advance TCM formulations with modern R&D and quality control
- Expand global distribution while maintaining affordability
Vision
Lingrui's vision is to be a leading bridge between traditional Chinese therapeutics and modern pharmaceutical innovation-recognized domestically and internationally for reliable TCM-derived products, high-volume adhesive-plaster manufacturing, and continuous R&D that converts traditional knowledge into scalable, regulated healthcare solutions.- Position as a global supplier of trusted TCM and allied products
- Scale production capacity-especially in adhesive plasters-to meet rising global demand
- Develop internationally recognized product lines supported by clinical and quality data
Core Values
- Quality-first: rigorous quality control from raw herbs to finished dosage forms
- Integrity: transparent compliance with regulatory and listing obligations
- Innovation: marrying TCM heritage with modern pharmaceutical science and manufacturing
- Customer focus: meeting clinical needs and market demand across domestic and export channels
- Sustainability: responsible sourcing and scalable production practices
Operational and Financial Snapshot
| Metric | Detail |
|---|---|
| Founded | 1999 |
| Stock Listing | Shanghai Stock Exchange, 2000 (600285.SS) |
| 2020 Revenue | 2.33 billion yuan |
| Main Production Base | Xin County, Henan Province (adhesive plasters) |
| Product Types | Tablets, injections, ointments, adhesive plasters, Chinese patent medicines |
| Export Reach | Over 30 countries |
Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) Overview
Mission StatementHenan Lingrui Pharmaceutical Co., Ltd. (600285.SS) exists to promote a healthier life for humankind through advancements in science, focusing on innovative healthcare solutions that enhance patient quality of life. The company is dedicated to research, development, production, and sales of pharmaceuticals and health products, pursuing high-quality, safe, and effective therapies while adhering to international standards such as GMP.
- R&D-driven: invested ~150 million yuan in R&D in 2022 (~12.5% of total revenue).
- Quality-first: GMP-compliant manufacturing and quality systems across production lines.
- Patient-centered: product choices and pipeline priorities prioritize clinical benefit and safety.
- Global ambition: target to become a first-class global pharmaceutical and healthcare enterprise by 2025.
The company's vision emphasizes leadership in specialty pharmaceuticals and health products through continuous innovation, strategic partnerships, and scalable manufacturing that meets both domestic and international regulatory expectations.
- Scale-up objective: expand manufacturing capacity and export footprint to enter new markets.
- Innovation pipeline: focus on therapeutic areas with high unmet need and strong market potential.
- Sustainability in operations: embed quality, environmental and social governance into growth plans.
Henan Lingrui's core values guide daily operations, R&D priorities, and stakeholder engagement.
- Integrity - transparent compliance with regulatory and ethical standards.
- Excellence - continuous improvement in product quality and clinical outcomes.
- Collaboration - cross-functional teamwork and external scientific partnerships.
- Responsibility - patient welfare and public health as central metrics of success.
| Metric | 2022 Value | Notes |
|---|---|---|
| Total Revenue (approx.) | 1.20 billion yuan | Derived from R&D share: 150M ≈ 12.5% of revenue |
| R&D Expenditure | 150 million yuan | ~12.5% of total revenue in 2022 |
| R&D Intensity | 12.5% | Reflects strategic emphasis on innovation |
| GMP Compliance | Certified | Applies to major production facilities |
| Strategic Target | Global first-class enterprise by 2025 | Focus on market expansion and quality leadership |
For a deeper dive into the company's financial position and investor-relevant metrics, see: Breaking Down Henan Lingrui Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors
Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) - Mission Statement
Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) positions its mission around delivering innovative, safe and effective pharmaceutical and healthcare solutions while accelerating global expansion. The mission is operationalized through a focus on R&D-driven product pipelines, strategic international partnerships, and disciplined capital allocation to scale biopharmaceutical capabilities.- Deliver high-quality medicines and healthcare products that meet global regulatory standards.
- Drive sustainable growth through continuous innovation and technological advancement.
- Expand global footprint via exports, licensing and joint ventures to serve broader patient populations.
- Operate with pragmatism, focus and diligence to convert scientific advances into commercial therapies.
- Short-term (by 2025): Emerge as a globally competitive Chinese pharmaceutical company with recognized product offerings in selected therapeutic areas.
- Long-term: Transform into a global biopharmaceutical group with diversified international revenues and a robust, innovation-led pipeline.
- Strategic pillars: R&D excellence, regulatory compliance, scaled manufacturing, and global commercialization.
| Metric / Target | Current Focus / Target by 2025 | Operational Rationale |
|---|---|---|
| Global market positioning | Become a first-class global enterprise by 2025 | Raise brand and product recognition in Asia, Europe, and select emerging markets |
| Revenue growth target | Average annual growth ~15-25% (strategic target range) | Organic growth + revenue from new international channels |
| R&D investment | Target ~6-10% of revenue reinvested in R&D | Support pipeline advancement and regulatory filings (CTAs/NDAs) |
| Export / international revenue share | Increase to ~25-35% of total revenue | Diversify markets, reduce single-market concentration risk |
| Product approvals (international) | Obtain multiple regulatory approvals in target markets by 2025 | Enable commercial launches and licensing opportunities |
| Operational efficiency | Continuous OPEX optimization and scaled manufacturing to improve margins by 3-7 p.p. | Support competitiveness and reinvestment capacity |
- Innovation-first R&D: Prioritize biologics, specialty small molecules and formulation technologies to build a differentiated pipeline.
- Global regulatory readiness: Strengthen regulatory affairs capabilities to accelerate approvals and WHO/EU/US-comparable registrations.
- Partnerships & M&A: Pursue selective licensing, co-development deals and capacity acquisitions to enter new geographies faster.
- Manufacturing scale-up: Invest in GMP-compliant facilities and contract manufacturing partnerships to meet international demand.
- Talent and culture: Embed pragmatic, focused and diligent behaviors across functions to translate strategy into execution.
Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) - Vision Statement
Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) anchors its corporate identity in a clear vision: to become a first-class enterprise in the global pharmaceutical and healthcare markets by 2025 through patient-centered care, sustainable innovation, operational excellence, and deep-rooted social responsibility.- Care for life: prioritizing patient health, safety, and access to effective therapies.
- Continuous pursuit of sustainable innovation: investing in R&D and technology to deliver novel and improved healthcare products.
- Excellence: driving quality, regulatory compliance, and manufacturing best practices.
- Partnership: collaborating with research institutions, healthcare providers, and communities to scale impact.
- People-first culture: employment creation and targeted poverty alleviation programs.
- Technology-driven growth: R&D and production modernization to meet international standards.
- Community stewardship: long-term commitments to Xin County's socioeconomic development.
| Metric | Value / Commitment |
|---|---|
| Target year for global first-class status | 2025 |
| Documented donations (cumulative) | More than RMB 20,000,000 |
| Poverty alleviation: people lifted out of poverty | More than 10,000 individuals |
| Employment impact | Provides jobs for thousands of local residents |
| Social programs supported | Disaster relief, infrastructure (bridges/roads), Hope Project, education, support for impoverished/disabled, care for widows and the elderly |
- R&D prioritization: allocate resources to compounds and formulations addressing major public health needs while pursuing sustainable processes.
- Quality and compliance: meet domestic and international regulatory requirements to support export and partnership ambitions.
- Socioeconomic investment: maintain and expand programs that generated >RMB 20M in donations and lifted >10,000 people from poverty.
Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.